Relapse Clinical Trials in Xiamen, Fujian
10 recruitingXiamen, Fujian, China
Showing 1–10 of 10 trials
Recruiting
Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
BeOne Medicines246 enrolled83 locationsNCT04973605
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Refractory Follicular LymphomaFollicular LymphomaRelapsed/Refractory Follicular Lymphoma
Epizyme, Inc.612 enrolled229 locationsNCT04224493
Recruiting
Phase 1Phase 2
A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Nanjing Leads Biolabs Co.,Ltd342 enrolled26 locationsNCT06049290
Recruiting
Phase 2
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
Leukemia, Myeloid, AcuteRefractory LeukemiaRelapsed Adult AML
The First Affiliated Hospital of Xiamen University30 enrolled1 locationNCT05305859
Recruiting
Phase 1
Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML
Acute Myeloid LeukemiaRelapseRefractory AML
The First Affiliated Hospital of Xiamen University30 enrolled1 locationNCT06737523
Recruiting
Phase 2
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
The First Affiliated Hospital of Xiamen University25 enrolled1 locationNCT06158412
Recruiting
Phase 2
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Peripheral T Cell LymphomaRelapsed Peripheral T-Cell LymphomaRefractory T-Cell Lymphoma
The First Affiliated Hospital of Xiamen University33 enrolled1 locationNCT06151106
Recruiting
Phase 2
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
Multiple MyelomaRelapsed/Refractory
The First Affiliated Hospital of Xiamen University5 enrolled1 locationNCT06581640